Personalized at‐home neurofeedback compared to long‐acting methylphenidate in children with ADHD: NEWROFEED, a European randomized noninferiority trial

2021 ◽  
Author(s):  
Diane Purper‐Ouakil ◽  
Hilario Blasco‐Fontecilla ◽  
Tomas Ros ◽  
Eric Acquaviva ◽  
Tobias Banaschewski ◽  
...  
Keyword(s):  
Children With Adhd ◽  
Noninferiority Trial ◽  
Long Acting ◽  
At Home

scholarly journals Personalized at-home neurofeedback compared with long-acting methylphenidate in an european non-inferiority randomized trial in children with ADHD

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Stéphanie Bioulac ◽  
Diane Purper-Ouakil ◽  
Tomas Ros ◽  
Hilario Blasco-Fontecilla ◽  
Marie Prats ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Children With Adhd ◽  
Long Acting ◽  
At Home

scholarly journals Does 20 mg long-acting methylphenidate alter blood pressure and heart rate in children with ADHD?

2011 ◽  
Vol 51 (5) ◽  
pp. 282
Author(s):  
Tjhin Wiguna ◽  
Sasanto Wibisono ◽  
Sudigdo Sastroasmoro ◽  
Fransiscus D. Suyatna
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Cardiovascular Effects ◽  
Children With Adhd ◽  
Normal Ranges ◽  
Blood Pressures ◽  
Drug Naïve ◽  
Repeated Analysis ◽  
Long Acting

Objective To identify the cardiovascular effects of long-acting methylphenidate administered for twelve weeks in Indonesian children with ADHD.Methods This was an 18-week, time series study on children with ADHD who were given 20 mg of long-acting methylphenidate for twelve weeks. During the study period we made ten serial observations of the subjects, including before, during and 6 weeks following drug administration. We included drug naive children with ADHD between the ages of 7 – 10 years. Children with mental retardation and chronic physical or mental disorders were excluded. Blood pressure was measured by sphygmomanometer with a child’s cuff at the brachial artery. We also collected data on heart rate, side effects, complaints and other medications used during the study. Repeated analysis was performed on the data with a P level of 0.05.Results Twenty-one subjects were recruited for this study. Mean blood pressure fluctuated insignificantly during the research period, for both mean systolic and mean diastolic blood pressures (P=0.115 and P=0.059). Mean heart rate also fluctuated insignificantly (P=0.091). All fluctuations were within the normal ranges. During the study, there were complaints of dizziness, nausea, and gastrointestinal upset, but they were reportedly mild and disappeared before the second week of observation.Conclusion Administration of 20 mg long-acting methylphenidate for twelve weeks in children with ADHD altered mean blood pressures and heart rates, but within the normal range for children of their age. However, cardiovascular risk observation is still needed when administering methylphenidate to children with ADHD, especially for those using the medication long-term.[Paediatr Indones. 2011;51:282-7].

Pharmacology of Adult ADHD with Stimulants

CNS Spectrums ◽  
2007 ◽  
Vol 12 (S6) ◽  
pp. 8-11 ◽  
Author(s):  
Thomas J. Spencer
Keyword(s):  
Primary Care Physicians ◽  
Adult Adhd ◽  
Brain Disorder ◽  
Stimulant Treatment ◽  
Children With Adhd ◽  
Adolescents And Adults ◽  
Stimulant Medications ◽  
Long Acting ◽  
Core Symptoms ◽  
The Brain

AbstractAttention-deficit/hyperactivity disorder (ADHD) is a lifelong condition that begins in childhood and continues with adult manifestations related to the core symptoms. Approximately 50% to 75% of children with ADHD continue to meet criteria for the disorder as adolescents and adults. Adults with the disorder increasingly present to primary care physicians, psychiatrists, and other practitioners for diagnosis and treatment. Understanding the diagnosis of ADHD in adults requires knowledge of age-dependent decline of symptoms over time. Retrospective recall of symptoms and impairment are valid methods of diagnosing the disorder. ADHD is also a brain disorder with a strong neurobiologic basis, complex etiology, and genetic component. Genetic and environmental vulnerabilities give rise to abnormalities in the brain and subsequent behavioral and cognitive deficits, which may produce the symptoms associated with ADHD. Magnetic resonance imaging studies of ADHD have provided evidence that abnormalities in the brain are caused by the disorder itself rather than treatment of the disorder. Psychiatric comorbidity is common among patients with ADHD and tends to complicate treatment. Acute and long-term use of long-acting stimulant formulations (methylphenidate and amphetamine compounds) have shown robust efficacy and tolerability consistent with the treatment response established in children with ADHD. Non-stimulant medications have demonstrated efficacy as well, and may be preferred in patients with tic and substance use disorders.In this expert roundtable supplement, Timothy E. Wilens, MD, reviews the epidemiology and clinical presentation of adult ADHD. Next, Joseph Biederman, MD, provides an overview of recent advances in the neurobiology of ADHD. Thomas J. Spencer, MD, reviews stimulant treatment of adult ADHD, and Lenard A. Adler concludes with a discussion of non-stimulant trials in adult ADHD.

Panel Discussion

CNS Spectrums ◽  
2007 ◽  
Vol 12 (S6) ◽  
pp. 14-14 ◽  
Keyword(s):  
Primary Care Physicians ◽  
Adult Adhd ◽  
Panel Discussion ◽  
Brain Disorder ◽  
Stimulant Treatment ◽  
Children With Adhd ◽  
Adolescents And Adults ◽  
Stimulant Medications ◽  
Long Acting ◽  
The Brain

AbstractAttention-deficit/hyperactivity disorder (ADHD) is a lifelong condition that begins in childhood and continues with adult manifestations related to the core symptoms. Approximately 50% to 75% of children with ADHD continue to meet criteria for the disorder as adolescents and adults. Adults with the disorder increasingly present to primary care physicians, psychiatrists, and other practitioners for diagnosis and treatment. Understanding the diagnosis of ADHD in adults requires knowledge of age-dependent decline of symptoms over time. Retrospective recall of symptoms and impairment are valid methods of diagnosing the disorder. ADHD is also a brain disorder with a strong neurobiologic basis, complex etiology, and genetic component. Genetic and environmental vulnerabilities give rise to abnormalities in the brain and subsequent behavioral and cognitive deficits, which may produce the symptoms associated with ADHD. Magnetic resonance imaging studies of ADHD have provided evidence that abnormalities in the brain are caused by the disorder itself rather than treatment of the disorder. Psychiatric comorbidity is common among patients with ADHD and tends to complicate treatment. Acute and long-term use of long-acting stimulant formulations (methylphenidate and amphetamine compounds) have shown robust efficacy and tolerability consistent with the treatment response established in children with ADHD. Non-stimulant medications have demonstrated efficacy as well, and may be preferred in patients with tic and substance use disorders.In this expert roundtable supplement, Timothy E. Wilens, MD, reviews the epidemiology and clinical presentation of adult ADHD. Next, Joseph Biederman, MD, provides an overview of recent advances in the neurobiology of ADHD. Thomas J. Spencer, MD, reviews stimulant treatment of adult ADHD, and Lenard A. Adler concludes with a discussion of non-stimulant trials in adult ADHD.

Defiance

2021 ◽  
pp. 47-53
Author(s):  
Mark Selikowitz
Keyword(s):  
Conduct Disorder ◽  
Prominent Feature ◽  
Children With Adhd ◽  
Oppositional Disorder ◽  
The Brain ◽  
At Home

Approximately one-quarter of children with ADHD experience significant difficulties in conforming to rules and regulations appropriate for their age, and these difficulties are usually seen both at home and at school. Parents of such children quickly learn that smacking and other forms of punishment are ineffective. Performance inconsistency, which is a prominent feature of ADHD, is often misinterpreted as implying that the child could succeed if only more effort were made. This chapter explores defiance in ADHD, including compliance as a function of the brain, the severity of defiant behaviour (oppositional disorder, conduct disorder), and the treatment of defiant behaviour.

ADHD: Prevalence, Diagnosis, and Issues of Comorbidity

CNS Spectrums ◽  
2007 ◽  
Vol 12 (S6) ◽  
pp. 1-5 ◽  
Author(s):  
Timothy E. Wilens
Keyword(s):  
Primary Care Physicians ◽  
Brain Disorder ◽  
Children With Adhd ◽  
Hyperactivity Disorder ◽  
Adolescents And Adults ◽  
Stimulant Medications ◽  
Long Acting ◽  
Core Symptoms ◽  
The Brain

AbstractAttention-deficit/hyperactivity disorder (ADHD) is a lifelong condition that begins in childhood and continues with adult manifestations related to the core symptoms. Approximately 50% to 75% of children with ADHD continue to meet criteria for the disorder as adolescents and adults. Adults with the disorder increasingly present to primary care physicians, psychiatrists, and other practitioners for diagnosis and treatment. Understanding the diagnosis of ADHD in adults requires knowledge of age-dependent decline of symptoms over time. Retrospective recall of symptoms and impairment are valid methods of diagnosing the disorder. ADHD is also a brain disorder with a strong neurobiologic basis, complex etiology, and genetic component. Genetic and environmental vulnerabilities give rise to abnormalities in the brain and subsequent behavioral and cognitive deficits, which may produce the symptoms associated with ADHD. Magnetic resonance imaging studies of ADHD have provided evidence that abnormalities in the brain are caused by the disorder itself rather than treatment of the disorder. Psychiatric comorbidity is common among patients with ADHD and tends to complicate treatment. Acute and long-term use of long-acting stimulant formulations (methylphenidate and amphetamine compounds) have shown robust efficacy and tolerability consistent with the treatment response established in children with ADHD. Non-stimulant medications have demonstrated efficacy as well, and may be preferred in patients with tic and substance use disorders.

Advances in the Neurobiology of ADHD

CNS Spectrums ◽  
2007 ◽  
Vol 12 (S6) ◽  
pp. 6-7 ◽  
Author(s):  
Joseph Biederman
Keyword(s):  
Primary Care Physicians ◽  
Adult Adhd ◽  
Brain Disorder ◽  
Stimulant Treatment ◽  
Children With Adhd ◽  
Adolescents And Adults ◽  
Stimulant Medications ◽  
Long Acting ◽  
Core Symptoms ◽  
The Brain

AbstractAttention-deficit/hyperactivity disorder (ADHD) is a lifelong condition that begins in childhood and continues with adult manifestations related to the core symptoms. Approximately 50% to 75% of children with ADHD continue to meet criteria for the disorder as adolescents and adults. Adults with the disorder increasingly present to primary care physicians, psychiatrists, and other practitioners for diagnosis and treatment. Understanding the diagnosis of ADHD in adults requires knowledge of age-dependent decline of symptoms over time. Retrospective recall of symptoms and impairment are valid methods of diagnosing the disorder. ADHD is also a brain disorder with a strong neurobiologic basis, complex etiology, and genetic component. Genetic and environmental vulnerabilities give rise to abnormalities in the brain and subsequent behavioral and cognitive deficits, which may produce the symptoms associated with ADHD. Magnetic resonance imaging studies of ADHD have provided evidence that abnormalities in the brain are caused by the disorder itself rather than treatment of the disorder. Psychiatric comorbidity is common among patients with ADHD and tends to complicate treatment. Acute and long-term use of long-acting stimulant formulations (methylphenidate and amphetamine compounds) have shown robust efficacy and tolerability consistent with the treatment response established in children with ADHD. Non-stimulant medications have demonstrated efficacy as well, and may be preferred in patients with tic and substance use disorders.In this expert roundtable supplement, Timothy E. Wilens, MD, reviews the epidemiology and clinical presentation of adult ADHD. Next, Joseph Biederman, MD, provides an overview of recent advances in the neurobiology of ADHD. Thomas J. Spencer, MD, reviews stimulant treatment of adult ADHD, and Lenard A. Adler concludes with a discussion of non-stimulant trials in adult ADHD.

A guide to specific medicines

2021 ◽  
pp. 156-180
Author(s):  
Mark Selikowitz
Keyword(s):  
Medical Specialist ◽  
Children With Adhd ◽  
Short Acting ◽  
Stimulant Medications ◽  
Day Of The Week ◽  
Long Acting

There are many different medications used for ADHD, and these should only be prescribed by a medical specialist experienced in this field. Many children with ADHD do not need to take their medication every day of the week. The availability of long-acting medication means that most children with ADHD do not need to take medication at school. This chapter presents a detailed guide to specific medicines for ADHD, including short-acting stimulant medicines (Ritalin, Focalin, dexamphetamine, and Adderall IR), long-acting stimulant medications (Concerta, Ritalin LA, Focalin XR, Daytrana, Adderall XR, Metadate CD, and Vyvanse), and non-stimulant medications (imipramine [Tofranil], Clonidine, guanfacine [Intuniv], and atomoxetine [Strattera]).

New Long-Acting Stimulants in Children With ADHD

2004 ◽  
Vol 17 (4) ◽  
pp. 177-179 ◽  
Author(s):  
Adrienne Rains ◽  
Lawrence Scahill
Keyword(s):  
Children With Adhd ◽  
Long Acting

Non-Stimulant Trials of Adult ADHD

CNS Spectrums ◽  
2007 ◽  
Vol 12 (S6) ◽  
pp. 11-13 ◽  
Author(s):  
Lenard A. Adler
Keyword(s):  
Primary Care Physicians ◽  
Adult Adhd ◽  
Brain Disorder ◽  
Stimulant Treatment ◽  
Children With Adhd ◽  
Adolescents And Adults ◽  
Stimulant Medications ◽  
Long Acting ◽  
Core Symptoms ◽  
The Brain

AbstractAttention-deficit/hyperactivity disorder (ADHD) is a lifelong condition that begins in childhood and continues with adult manifestations related to the core symptoms. Approximately 50% to 75% of children with ADHD continue to meet criteria for the disorder as adolescents and adults. Adults with the disorder increasingly present to primary care physicians, psychiatrists, and other practitioners for diagnosis and treatment. Understanding the diagnosis of ADHD in adults requires knowledge of age-dependent decline of symptoms over time. Retrospective recall of symptoms and impairment are valid methods of diagnosing the disorder. ADHD is also a brain disorder with a strong neurobiologic basis, complex etiology, and genetic component. Genetic and environmental vulnerabilities give rise to abnormalities in the brain and subsequent behavioral and cognitive deficits, which may produce the symptoms associated with ADHD. Magnetic resonance imaging studies of ADHD have provided evidence that abnormalities in the brain are caused by the disorder itself rather than treatment of the disorder. Psychiatric comorbidity is common among patients with ADHD and tends to complicate treatment. Acute and long-term use of long-acting stimulant formulations (methylphenidate and amphetamine compounds) have shown robust efficacy and tolerability consistent with the treatment response established in children with ADHD. Non-stimulant medications have demonstrated efficacy as well, and may be preferred in patients with tic and substance use disorders.In this expert roundtable supplement, Timothy E. Wilens, MD, reviews the epidemiology and clinical presentation of adult ADHD. Next, Joseph Biederman, MD, provides an overview of recent advances in the neurobiology of ADHD. Thomas J. Spencer, MD, reviews stimulant treatment of adult ADHD, and Lenard A. Adler concludes with a discussion of non-stimulant trials in adult ADHD.

Sign in / Sign up

Export Citation Format

Share Document